zur Navigation zum Inhalt


Immunotherapy: management of toxicity

02/2016 The basis underlying the toxicities of immune checkpoint inhibitors is their promotion of T-cell activity in a physiological manner. “The amplification of the immune system results in autoimmunity,” explained Ross Soo, MD, FRACP, National University Cancer Institute, Singapore.

Common AEs include fatigue, anorexia and arthralgia. Terms that denote immune-related adverse events (irAEs) typically end in -itis or -opathy. [...]

Mehr zum Thema

<< Seite 1 >>

Risks and chances in patients with oligometastatic disease

02/2016 Against the background of improved systemic therapies, there are rising expectations with regard to the potential cure of NSCLC patients who have a limited number of haematogeneous metastases. “Most studies define oligometastasis as one to three, or one to five lesions,” explained Suresh Senan, MRCP, FRCR, PhD, VU University Medical Centre, Amsterdam, The Netherlands [1]. [...]

Immunotherapy: anti-tumour activity despite extensive pretreatment

02/2016 The anti-PD-1-antibodies pembrolizumab and nivolumab have been shown to be active in lung cancer. Pembrolizumab is a high-affinity, humanised, monoclonal IgG4κ antibody against PD-1 that prevents the interaction of the receptor with PD-L1 and PD-L2. [...]

Intracranial activity of ceritinib in crizotinib-pretreated and crizotinib-naïve ALK-positive NSCLC patients

02/2016 In 3 % to 5 % of cases, lung cancer is associated with _ALK_ rearrangement and can therefore be targeted with the ALK inhibitors crizotinib and ceritinib. While crizotinib is the standard first-line therapy, ceritinib has gained approval for use with patients who are crizotinib-refractory. [...]

Disease progression on EGFR TKI therapy: what to do after erlotinib, gefitinib and afatinib?

02/2016 First-line treatment for patients with _EGFR_-mutation-positive NSCLC includes the first-generation reversible EGFR TKI inhibitors erlotinib and gefitinib, and the second-generation ErbB family blocker, afatinib. [...]

EGFR-mutation-positive NSCLC: expanding the data pool for established treatment options

02/2016 Subgroup analyses of LUX-Lung 3 and 6

Non–small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (_EGFR_) mutations represents a defined molecular subset of lung cancer that can be targeted with _EGFR_ tyrosine kinase inhibitor (TKI) therapies. [...]

Das Treffen der Onko-Primare

02/2016 Kürzlich trafen sich hochrangige Vertreter der Onkologie. Ihr Fazit: Durch die Fortschritte in der Krebstherapie konnte die Lebenserwartung und -qualität der Krebspatienten deutlich verbessert werden.

In den vergangenen Jahren gab es im Bereich der Onkologie eine rasante Entwicklung neuer Diagnostiken und Therapien. [...]

Medizin heute

Aktuelle Printausgaben